Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Approval for Ulcerative Colitis

 Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Approval for Ulcerative Colitis

Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Pfizer’s Xeljanz XR (tofacitinib) Receives the US FDA’s Approval for Ulcerative Colitis Approval for Ulcerative Colitis

Shots:

  • The US FDA has approved Xeljanz XR extended-release (11 & 22mg, qd) for the treatment of mod. to sev. active UC, after an inadequate response or intolerance to TNF blockers
  • Pfizer will advance the science of JAK inhibition and enhance the understanding of Xeljanz XR via robust clinical development programs in the treatment of immune-mediated inflammatory conditions
  • Xeljanz XR (qd) is the first and only JAK inhibitor, which allows patients living with mod. to sev. active UC to manage their disease and has received approval in 130+ countries for moderately to severely active RA, UC, and PsA

Click here to­ read full press release/ article | Ref: Pfizer | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post